DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hydromet (Hydrocodone Bitartrate / Homatropine Methylbromide) - Summary

 
 



HYDROMET SUMMARY

This product contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage.

HYDROMET (HYDROCODONE/METHYLHOMATROPINE) is indicated for the following:

For the symptomatic relief of cough.


See all Hydromet indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Hydromet (Hydrocodone / Homatropine)

Study finds e-cigarette use linked to cough reflex sensitivity
Source: Respiratory / Asthma News From Medical News Today [2015.08.21]
The popularity of electronic cigarettes has steadily increased worldwide, but little is known about their effects on health.

Cough
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2015.06.16]
Title: Cough
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/16/2015 12:00:00 AM

Is a Cough Contagious?
Source: MedicineNet Croup Specialty [2015.05.28]
Title: Is a Cough Contagious?
Category: Diseases and Conditions
Created: 5/28/2015 12:00:00 AM
Last Editorial Review: 5/28/2015 12:00:00 AM

Preteen Whooping Cough Vaccine Loses Strength Over Time, CDC Finds
Source: MedicineNet Immunizations Specialty [2015.05.04]
Title: Preteen Whooping Cough Vaccine Loses Strength Over Time, CDC Finds
Category: Health News
Created: 5/4/2015 12:00:00 AM
Last Editorial Review: 5/4/2015 12:00:00 AM

Children's Cough Causes and Treatments
Source: MedicineNet Croup Specialty [2015.01.22]
Title: Children's Cough Causes and Treatments
Category: Diseases and Conditions
Created: 11/19/2012 12:00:00 AM
Last Editorial Review: 1/22/2015 12:00:00 AM

more news >>

Published Studies Related to Hydromet (Hydrocodone / Homatropine)

Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. [2003.01]
RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers... CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.

more studies >>

Clinical Trials Related to Hydromet (Hydrocodone / Homatropine)

Single Dose Pharmacokinetics of Egalet´┐Ż Hydrocodone [Completed]

Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients [Completed]
Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction [Completed]
The purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain [Completed]
The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their current stable analgesic regimen

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. [Completed]
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.

more trials >>


Page last updated: 2015-08-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015